A short and concise response that I need help interpreting. Although bexmarilimab has been studied specifically in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), where TP53 mutations are common and have a poor prognosis, the drug does not require these mutations to work. Its efficacy is based on its ability to break down the immune protection built by the tumor. But Clark__kent, by those targeted drugs, do you mean those already on the market like AZA etc.? And if not, could you provide some candidates under development as investment tips?
3 Likes